Overview A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI Status: RECRUITING Trial end date: 2025-07-01 Target enrollment: Participant gender: Summary An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.Phase: PHASE2 Details Lead Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.